Gc Biopharma Sustainability Profile
Gc Biopharma, officially known as Green Cross Biopharma, is a leading biopharmaceutical company headquartered in South Korea (KR). Established in 1967, the company has made significant strides in the biopharmaceutical industry, focusing on the development and production of innovative therapies, particularly in the fields of immunology and infectious diseases. With a strong presence in Asia and expanding operations globally, Gc Biopharma is renowned for its core products, including plasma-derived therapies and vaccines. These offerings are distinguished by their high quality and efficacy, positioning the company as a trusted provider in the healthcare sector. Notable achievements include its commitment to research and development, which has propelled Gc Biopharma to a prominent market position, making it a key player in the biopharmaceutical landscape.
DitchCarbon Score
How does Gc Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Gc Biopharma's score of 16 is lower than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Gc Biopharma's reported carbon emissions
In 2023, GC Biopharma, headquartered in South Korea (KR), reported Scope 1 emissions of approximately 2,564,000 kg CO2e. This figure represents a decrease from 2022, where Scope 1 emissions were about 3,210,000 kg CO2e. The company has not disclosed any Scope 2 or Scope 3 emissions data for the years reported. GC Biopharma's emissions data is cascaded from its parent company, GC Biopharma Corp., which provides a broader context for its sustainability efforts. The company has not set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges, indicating a potential area for future commitment. The reported emissions intensity for 2023 was approximately 0.00005356 kg CO2e per unit of revenue, reflecting the company's ongoing efforts to monitor and manage its carbon footprint. As a current subsidiary of GC Biopharma Corp., the company is positioned within a corporate family that may influence its sustainability strategies moving forward.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | |
|---|---|
| Scope 1 | 14,362,000 |
| Scope 2 | 53,804,000 |
| Scope 3 | 4,567,000 |
How Carbon Intensive is Gc Biopharma's Industry?
How Carbon Intensive is Gc Biopharma's Location?
Gc Biopharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Gc Biopharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
